GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Trial Data] phase 2 biopsy endpoints, and what "resolution" means — 50 comments in the full submission. View in context.
925
c/survodutide·submitted 6 days ago by u/thermal_mass_tom

[Trial Data] phase 2 biopsy endpoints, and what "resolution" means

Trial Databranch of 8 comments

Thinking out loud about this: phase 2 biopsy endpoints, and what "resolution" means. The honest evidence position, written out so this board does not drift. Phase 2 data exists in a specific, biopsy-characterised population, with a slow protocol escalation and tolerability tables worth reading in full. Nothing…

Read the full submission and all 50 comments →

This branch

8 comments, started 6 days ago
u/julia_mensa110 points·6 days ago

Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.

replysharereportpermalink
u/tuva_kirchner50 points·5 days ago

Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.

replysharereportpermalink
u/elin_tamm12 points·5 days ago

the weight numbers are secondary to what this is being developed for

replysharereportpermalink
u/chidi_demir24 points·5 days ago

MASH endpoints are histological, which is a much harder bar

replysharereportpermalink
u/cormac_danquah10 points·5 days ago

independent testing on this compound is very thin

replysharereportpermalink
u/paper_trail_paulavetting14 points·5 days ago

Cosigning on the glucagon arm. It is the mechanistic thread that connects the hepatic and the metabolic effects.

replysharereportpermalink
u/thermal_mass_tomOP-7 points·5 days ago

Which phase and which arm are you quoting?

replysharereportpermalink
u/endotoxin_elliemicro1 point·5 days ago

the hepatic data is what makes this compound different from the others

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →